Clinical and Translational Medicine (Apr 2022)

Hepatocellular carcinoma‐infiltrating γδ T cells are functionally defected and allogenic Vδ2+ γδ T cell can be a promising complement

  • Wenjing He,
  • Yi Hu,
  • Dan Chen,
  • Yijia Li,
  • Dongmei Ye,
  • Qiang Zhao,
  • Li Lin,
  • Xiaomin Shi,
  • Ligong Lu,
  • Zhinan Yin,
  • Xiaoshun He,
  • Yifang Gao,
  • Yangzhe Wu

DOI
https://doi.org/10.1002/ctm2.800
Journal volume & issue
Vol. 12, no. 4
pp. n/a – n/a

Abstract

Read online

Abstract In hepatocellular carcinoma (HCC), γδ T cells participate in mediating the anti‐tumour response and are linked with a positive prognosis. However, these cells can become pro‐tumoural in the tumour microenvironment (TME). We aimed to decipher the immune landscape and functional states of HCC‐infiltrating γδ T cells to provide fundamental evidence for the adoptive transfer of allogeneic Vδ2+ γδ T cells in HCC immunotherapy. We performed single‐cell RNA sequencing (scRNA‐seq) on γδ T cells derived from HCC tumours and healthy donor livers. Confocal microscopy, flow cytometry and a Luminex assay were applied to validate the scRNA‐seq findings. The γδ T cells in the HCC TME entered G2/M cell cycle arrest, and expressed cytotoxic molecules such as interferon‐gamma and granzyme B, but were functionally exhausted as indicated by upregulated gene and protein LAG3 expression. The γδ T cells in the HCC TME were dominated by the LAG3+Vδ1+ population, whereas the Vδ2+ γδ T population was greatly depleted. Moreover, glutamine metabolism of γδ T cells was markedly upregulated in the glutamine‐deficient TME. Both in vitro and in vivo experiments showed that glutamine deficiency upregulated LAG3 expression. Finally, our results indicated that ex vivo‐expanded Vδ2+ γδ T cells from healthy donor could complement the loss of T cell receptor clonality and effector functions of HCC‐derived γδ T cells. This work deciphered the dysfunctional signatures of HCC‐infiltrating γδ T cells in the HCC TME, providing scientific support for the use of allogeneic Vδ2+ γδ T cells in HCC cellular therapy.

Keywords